Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tivozanib + temsirolimus
- Development stage
- Unknown
- Lead developer
- AVEO Oncology
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Tivozanib + temsirolimus is a combination therapy investigated for the treatment of advanced renal cell carcinoma (RCC). Tivozanib is a potent and selective small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3, thereby inhibiting tumor angiogenesis and growth. Temsirolimus is an mTOR inhibitor that binds to FKBP12 to inhibit the mammalian target of rapamycin pathway, resulting in cell cycle arrest at G1 phase and reduced synthesis of proteins involved in proliferation, survival, and angiogenesis. The combination has demonstrated acceptable tolerability with manageable toxicity in early-phase clinical studies for RCC[2][3][5].
- Brand names
- Fotivda (tivozanib)Torisel (temsirolimus)
- Other names
- tivozanib + temsirolimus
02
Targets
Mechanistic target of rapamycin complex 1VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on tivozanib + temsirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tivozanib + temsirolimus.